Written by Grant Zeng (CFA), Senior Biotech Analyst – Zacks Small Cap Research
EpiCept (EPCT) is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management.
The Company possesses an approved cancer product and a deep and balanced pipeline of three major clinical product candidates, including:
- EpiCept NP-1, a pain medication that has completed Phase II clinical trials
- Crolibulin™, an apoptosis inducer for solid vascularized tumors that is currently in Phase I clinical trials
- Azixa, an oncology compound that is currently in Phase II trials for brain cancer
Both cancer treatment and pain management are multi-billion dollar markets and with an approved product on the market and a decent pipeline, EpiCept boasts a preferable risk/benefit profile among its peers.
EpiCept is headquartered in Tarrytown, New York, and also possesses an in-house clinical research unit in Munich, Germany, which is managing the European clinical development of drug candidates.
EpiCept is listed on both the NASDAQ Capital Market and the OMX Nordic Exchange, under the symbol EPCT.
In this video, EpiCepts CEO, Jack Talley, discusses the potential for his company http://execvid.com/epicept
EPICEPT CORP (EPCT): Free Stock Analysis Report
Zacks Investment Research
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!